Havrix Junior (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix Junior is indicated for the prevention of hepatitis A infection in pediatric populations.

• Active immunization of children aged 1‑15 years.
• Part of routine childhood vaccination schedules in regions with hepatitis A risk.
• May be used for travelers to endemic areas when given before departure.
• Can be administered to individuals with chronic liver disease to reduce risk of severe hepatitis A.

The safety profile of Havrix Junior includes both common, generally mild reactions and rare, serious events.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever.
• Headache.
• Fatigue or malaise.
• Nausea.

Serious

• Severe allergic reaction (anaphylaxis).
• Guillain‑Barré syndrome (rare).
• High fever with convulsions.
• Persistent joint pain.

Before administering Havrix Junior, certain precautions should be considered to ensure safe use.

• Do not vaccinate individuals with a known severe allergy to any vaccine component, including algeldrate.
• Defer vaccination in persons experiencing acute moderate or severe illness.
• Assess immune status in immunocompromised patients; vaccine may be less effective.
• Discuss pregnancy and breastfeeding status with a healthcare provider, as safety data are limited.
• Monitor for signs of an allergic reaction for at least 15 minutes after injection.

Havrix Junior may interact with other substances, requiring attention to avoid or use with caution.

Avoid

• Concurrent administration of other injectable vaccines at the same anatomical site.
• Use of immunoglobulins or blood products within 2 weeks before or after vaccination (may reduce immune response).

Use with caution

• Antipyretics (e.g., acetaminophen) taken prophylactically may blunt antibody response; consider use after vaccination if needed.
• Live vaccines given within 4 weeks before or after Havrix Junior.
• Immunosuppressive therapy may diminish vaccine efficacy.